Published on : Mar 03, 2016
ALBANY, New York, March 03, 2016 – ResearchMoz.us has announced the addition of the report, titled “Global Allergic Rhinitis Drugs Market 2016-2020.” This report offers a strategic outlook on the global allergic rhinitis drugs market. According to the report, the global allergic rhinitis drugs market will expand at a 0.95% CAGR during the forecast period from 2016 to 2020.
Allergic rhinitis is caused by the interaction of airborne allergens with a specific IgE type antibody on the surface of mast cells. This reaction causes mast cells to release and synthesize chemicals, leading to inflammation of the surrounding tissues. Some of the common symptoms of allergic rhinitis are sneezing, nasal itching, rhinorrhea, and nasal congestion. The extranasal symptoms of the condition include itchy ears, conjunctivitis, itchy palate, and asthma. Some of the medications used to treat allergic rhinitis are antihistamines, immunotherapies, and intranasal corticosteroids. In certain cases, alternative forms of treatments are used to treat this disorder.
Click here to get more info with TOC in a PDF Format: https://www.researchmoz.us/enquiry.php?type=S&repid=565522
The global allergic rhinitis drugs market is driven by the significant rise in the prevalence of allergic rhinitis. According to a study conducted by the American College of Allergy, Asthma & Immunology, in 2014, there were at least 50 mn people in the United States alone suffering from allergic rhinitis. The main causes of allergic rhinitis are genetic factors and factors such as exposure to animals or vehicular pollution. This trend is projected to drive people to seek treatment for the disorder, in turn driving the demand for allergic rhinitis drugs.
At present, consumers in the global allergic rhinitis drugs market are increasingly opting for self-medication by using over-the-counter (OTC) drugs. This trend is projected to significantly fuel the overall allergic rhinitis drugs market. Furthermore, the introduction of favorable regulatory policies has led to the growing preference for OTC drugs as compared to prescribed drugs. Consumers can buy OTC drugs without any prescription and people suffering from mild allergic rhinitis can also buy these drugs for self-medication.
Another prominent trend driving the global allergic rhinitis drugs market is the growing number of research and development activities. Besides R&D, companies in the global allergic rhinitis drugs market are also focusing on strategic alliances. Nevertheless, the global allergic rhinitis drugs market will also be challenged by the adverse effects of allergic rhinitis drugs. Moreover, the increasing preference for CAM and the rising number of patent expiries will also suppress the global allergic rhinitis drugs market. Another key restraint on the global allergic rhinitis drugs market is the growing competition from generic drugs.
The key players operating in the global allergic rhinitis drugs market are Sanofi, UCB, Merck, GlaxoSmithKline, AstraZeneca, and Meda Pharmaceuticals. Each key player is analyzed in the report with its product portfolio, top selling drugs, geographical segmentation by revenue, and key strategies. This will offer a clear perspective to readers on the competitive landscape of the global allergic rhinitis drugs market.
To order report Call USA – Canada Toll Free: 866-997-4948 or send an email on firstname.lastname@example.org